{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:28:31Z","timestamp":1763036911481,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ad.2015.02.008","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T17:46:59Z","timestamp":1431020819000},"page":"e33-e39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tratamiento del s\u00edndrome de S\u00e9zary con alemtuzumab: serie de 5 casos y revisi\u00f3n de la literatura"],"prefix":"10.1016","volume":"106","author":[{"given":"E.","family":"del Alc\u00e1zar-Viladomiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tuneu-Valls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"L\u00f3pez-Pesta\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Vidal-Mance\u00f1ido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2015.02.008_bib0095","doi-asserted-by":"crossref","first-page":"205e1","DOI":"10.1016\/j.jaad.2013.07.049","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part I diagnosis: Clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2015.02.008_bib0100","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2015.02.008_bib0105","doi-asserted-by":"crossref","first-page":"223e1","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part II prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2015.02.008_bib0110","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: Clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ad.2015.02.008_bib0115","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ad.2012.01.011","article-title":"Actualizaci\u00f3n terap\u00e9utica en linfomas cut\u00e1neos","volume":"103","author":"Izu-Belloso","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2015.02.008_bib0120","doi-asserted-by":"crossref","first-page":"117ra117","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ad.2015.02.008_bib0125","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1200\/JCO.1998.16.10.3257","article-title":"CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma","volume":"16","author":"Lundin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2015.02.008_bib0130","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ad.2015.02.008_bib0135","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"De Masson","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2015.02.008_bib0140","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and S\u00e9zary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ad.2015.02.008_bib0145","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.11551","article-title":"Phase II study of alemtuzumab in chronic lymphoproliferative disorders","volume":"98","author":"Ferrajoli","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ad.2015.02.008_bib0150","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1385\/MO:20:4:389","article-title":"Mycosis fungoides\/S\u00e9zary syndrome: A report of three cases treated with Campath-1H as salvage treatment","volume":"20","author":"Capalbo","year":"2003","journal-title":"Med Oncol"},{"key":"10.1016\/j.ad.2015.02.008_bib0155","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","article-title":"Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/S\u00e9zary syndrome","volume":"104","author":"Lenihan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ad.2015.02.008_bib0160","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ad.2015.02.008_bib0165","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.leukres.2007.11.009","article-title":"Subcutaneous alemtuzumab for S\u00e9zary syndrome in the very elderly","volume":"32","author":"Alinari","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.ad.2015.02.008_bib0170","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: A single institution experience from the Robert H Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ad.2015.02.008_bib0175","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jamadermatol.2013.10099","article-title":"Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: Diffuse erythema as a positive predictor of complete remission","volume":"150","author":"Watanabe","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2015.02.008_bib0180","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/jamadermatol.2013.10615","article-title":"Cutaneous hemophagocytosis after alemtuzumab injection in a patient with S\u00e9zary syndrome","volume":"150","author":"Jawed","year":"2014","journal-title":"JAMA Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731015001477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731015001477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:02:57Z","timestamp":1757552577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731015001477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0001731015001477"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2015.02.008","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento del s\u00edndrome de S\u00e9zary con alemtuzumab: serie de 5 casos y revisi\u00f3n de la literatura","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2015.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}